“Editas Medicines’ differentiated approach for potentially treating sickle cell disease and beta-thalassemia is currently preclinical. Data presented at 2018 ASH demonstrated in vivo an increased production of fetal hemoglobin, which can be beneficial to patients with sickle cell disease or beta-thalassemia. HBG1/2 site is a differentiated approach for development of a human therapeutic for the treatment of sickle cell disease and beta-thalassemia as compared to other medicines currently under development that edit at the BCL11Ae site. These results could lead to further development in this setting.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 6.9% and a 46.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine Inc with a $43.67 average price target.
Based on Editas Medicine Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.24 million. In comparison, last year the company had a GAAP net loss of $26.6 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).